NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES
VICTORIA, British Columbia, July 13, 2017 -- Evergreen Medicinal Supply Inc. (“Evergreen”) is pleased to announce that it has commenced cultivation of medical cannabis at its licensed facility, pursuant to its ACMPR (“Access to Cannabis for Medical Purposes Regulations”) license from Health Canada, granted on March 16th, 2017.
Evergreen’s founder and CEO Shawn Galbraith commented, “The beginning of actual medical cannabis cultivation at our facility, which features a diversified strain selection, is another significant milestone for Evergreen Medicinal Supply. It is the intent of Evergreen to imminently apply for additional permitted activities to our ACMPR license at the earliest available opportunity, including the selling of dried cannabis flower, and the cultivation and sale of cannabis oil, as permitted under the ACMPR.
Evergreen has recently entered into a wholesale sales agreement with another Licensed Producer under the ACMPR program. Pursuant to this agreement, Evergreen has agreed to sell on a wholesale basis up to 30 kilograms of bulk-dried cannabis a month. Galbraith commented, “The starting of cannabis cultivation in concert with entering into a wholesale sales contract with a high performing Licensed Producer accelerates Evergreen’s development and provides a clear path to predictable revenue." Together these activities fortify Evergreen as it begins to operate under its license, and plans for its significant facility expansion anticipated commencing in 2017.
Evergreen Medicinal Supply recently entered into an interim agreement with Cannabis Wheaton Income Corp (“CW”) (TSX VENTURE:CBW). Pursuant to this agreement, CW will invest the sum of $25,000,000.00 Canadian into Evergreen. The proceeds will be deployed to fund the construction of a 150,000 square foot purpose built cannabis cultivation facility providing an additional 75,000 square feet of growing area (building 2) to be operated by Evergreen. CW will receive shares in Evergreen equivalent to 6.6% of the Corporation’s current outstanding shares. CW will additionally receive a stream equal to the lesser of: i) 33% of the total cannabis production generated within Building 2, or ii) 5,000,000 grams of cannabis per year from Building 2. This stream will commence upon Evergreen providing CW with its first allocation under this agreement, and then continues for a fixed term of ten years. Galbraith commented, “The interim agreement entered into with Cannabis Wheaton has secured for Evergreen the capital necessary to begin construction of one of the largest purpose built indoor cannabis production facilities in the world. Building 2 will allow Evergreen to increase production to 30,000 kilograms of dried cannabis per year. We anticipate that Building 2 will be completed by the summer of 2018. This expansion provides Evergreen with the production footprint to meet the overwhelming demand anticipated for our products over the years to come."
ABOUT EVERGREEN MEDICINAL SUPPLY INC.
Born and bred in historic Victoria, British Columbia, Evergreen Medicinal Supply currently operates out of a 5,700 square foot licensed facility, located on a 2.9-acre parcel of agricultural land. In compliance with current local zoning, the site is permitted to house in excess of 150,000 square feet of production space. Evergreen embraces advanced growing techniques, and will incorporate many of the innovations that the industry has developed over the last several years. The company has a very clear mission to support the local community, and is owned and operated by citizens of Victoria.
CONTACT INFORMATION Evergreen Medicinal Supply Corporation [email protected]


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Apple Turns 50: From Garage Startup to AI Crossroads
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



